Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke

Mohammad Reza Amiri-Nikpour,1 Surena Nazarbaghi,1 Babak Ahmadi-Salmasi,1 Tayebeh Mokari,2 Urya Tahamtan,2 Yousef Rezaei3 1Department of Neurology, Imam Khomeini Hospital, 2School of Medicine, 3Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran Background: Cerebrolys...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/26fdf02414b74d73bfd17b18cf477571
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26fdf02414b74d73bfd17b18cf477571
record_format	dspace
spelling	oai:doaj.org-article:26fdf02414b74d73bfd17b18cf4775712021-12-02T00:04:05ZCerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke1178-2021https://doaj.org/article/26fdf02414b74d73bfd17b18cf4775712014-12-01T00:00:00Zhttp://www.dovepress.com/cerebrolysin-effects-on-neurological-outcomes-and-cerebral-blood-flow--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Mohammad Reza Amiri-Nikpour,1 Surena Nazarbaghi,1 Babak Ahmadi-Salmasi,1 Tayebeh Mokari,2 Urya Tahamtan,2 Yousef Rezaei3 1Department of Neurology, Imam Khomeini Hospital, 2School of Medicine, 3Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran Background: Cerebrolysin, a brain-derived neuropeptide, has been shown to improve the neurological outcomes of stroke, but no study has demonstrated its effect on cerebral blood flow. This study aimed to determine the cerebrolysin impact on the neurological outcomes and cerebral blood flow. Methods: In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily. All patients were examined using the National Institutes of Health Stroke Scale and transcranial Doppler to measure the mean flow velocity and pulsatility index (PI) of their cerebral arteries at baseline as well as on days 30, 60, and 90. Results: The patients’ mean age was 60±9.7 years, and 51.2% of patients were male. The National Institutes of Health Stroke Scale was significantly lower in the cerebrolysin group compared with the placebo group on day 60 (median 10, interquartile range 9–11, P=0.008) and day 90 (median 11, interquartile range 10–13.5, P=0.001). The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05). One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%). Conclusion: Cerebrolysin can be useful to improve the neurological outcomes and the PI of middle cerebral artery in patients with acute focal ischemic stroke. Keywords: ischemic stroke, cerebrolysin, neuroprotection, NIHSS, mean flow velocity, pulsatility indexAmiri-Nikpour MRNazarbaghi SAhmadi-Salmasi BMokari TTahamtan URezaei YDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 2299-2306 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Amiri-Nikpour MR Nazarbaghi S Ahmadi-Salmasi B Mokari T Tahamtan U Rezaei Y Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke
description	Mohammad Reza Amiri-Nikpour,1 Surena Nazarbaghi,1 Babak Ahmadi-Salmasi,1 Tayebeh Mokari,2 Urya Tahamtan,2 Yousef Rezaei3 1Department of Neurology, Imam Khomeini Hospital, 2School of Medicine, 3Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran Background: Cerebrolysin, a brain-derived neuropeptide, has been shown to improve the neurological outcomes of stroke, but no study has demonstrated its effect on cerebral blood flow. This study aimed to determine the cerebrolysin impact on the neurological outcomes and cerebral blood flow. Methods: In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily. All patients were examined using the National Institutes of Health Stroke Scale and transcranial Doppler to measure the mean flow velocity and pulsatility index (PI) of their cerebral arteries at baseline as well as on days 30, 60, and 90. Results: The patients’ mean age was 60±9.7 years, and 51.2% of patients were male. The National Institutes of Health Stroke Scale was significantly lower in the cerebrolysin group compared with the placebo group on day 60 (median 10, interquartile range 9–11, P=0.008) and day 90 (median 11, interquartile range 10–13.5, P=0.001). The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05). One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%). Conclusion: Cerebrolysin can be useful to improve the neurological outcomes and the PI of middle cerebral artery in patients with acute focal ischemic stroke. Keywords: ischemic stroke, cerebrolysin, neuroprotection, NIHSS, mean flow velocity, pulsatility index
format	article
author	Amiri-Nikpour MR Nazarbaghi S Ahmadi-Salmasi B Mokari T Tahamtan U Rezaei Y
author_facet	Amiri-Nikpour MR Nazarbaghi S Ahmadi-Salmasi B Mokari T Tahamtan U Rezaei Y
author_sort	Amiri-Nikpour MR
title	Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke
title_short	Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke
title_full	Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke
title_fullStr	Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke
title_full_unstemmed	Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke
title_sort	cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/26fdf02414b74d73bfd17b18cf477571
work_keys_str_mv	AT amirinikpourmr cerebrolysineffectsonneurologicaloutcomesandcerebralbloodflowinacuteischemicstroke AT nazarbaghis cerebrolysineffectsonneurologicaloutcomesandcerebralbloodflowinacuteischemicstroke AT ahmadisalmasib cerebrolysineffectsonneurologicaloutcomesandcerebralbloodflowinacuteischemicstroke AT mokarit cerebrolysineffectsonneurologicaloutcomesandcerebralbloodflowinacuteischemicstroke AT tahamtanu cerebrolysineffectsonneurologicaloutcomesandcerebralbloodflowinacuteischemicstroke AT rezaeiy cerebrolysineffectsonneurologicaloutcomesandcerebralbloodflowinacuteischemicstroke
_version_	1718403915145281536

Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke

Ejemplares similares